Atlas Venture Life Science Advisors is an investment fund managing more than $598 million ran by Ommer Chohan. There are currently 16 companies in Chohan’s portfolio. The largest investments include Day One Biopharmaceuticals, Inc. and Kymera Therapeutics, together worth $296 million.
As of 27th July 2022, Atlas Venture Life Science Advisors’s top holding is 8,968,305 shares of Day One Biopharmaceuticals, Inc. currently worth over $161 million and making up 26.8% of the portfolio value.
In addition, the fund holds 6,875,698 shares of Kymera Therapeutics worth $135 million, whose value fell 43.7% in the past six months.
The third-largest holding is Dyne Therapeutics worth $61.4 million and the next is Replimune Inc worth $56.1 million, with 3,209,627 shares owned.
Currently, Atlas Venture Life Science Advisors's portfolio is worth at least $598 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Atlas Venture Life Science Advisors office and employees reside in Cambridge, Massachusetts. According to the last 13-F report filed with the SEC, Ommer Chohan serves as the CFO at Atlas Venture Life Science Advisors.
In the most recent 13F filing, Atlas Venture Life Science Advisors revealed that it had increased its stake in
Day One Biopharmaceuticals, Inc. and bought 766,667 additional shares worth around .
On the other hand, there are companies that Atlas Venture Life Science Advisors is getting rid of from its portfolio.
Atlas Venture Life Science Advisors closed its position in Cogent Biosciences on 3rd August 2022.
It sold the previously owned 186,487 shares for $1.4 million.
Ommer Chohan also disclosed a decreased stake in Aerovate Therapeutics, Inc. by 0.2%.
This leaves the value of the investment at $41.2 million and 2,638,297 shares.
The two most similar investment funds to Atlas Venture Life Science Advisors are Vantagepoint Investment Advisers and Plante Moran Advisors. They manage $598 million and $598 million respectively.
Atlas Venture Life Science Advisors’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 56.4% of
the total portfolio value.
The fund focuses on investments in the United States as
50.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
19% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $447 million.
These positions were updated on August 3rd based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Day One Biopharmaceuticals, Inc. |
9.35%
8,968,305
|
$160,533,000 | 26.84% |
| Kymera Therapeutics, Inc. |
No change
6,875,698
|
$135,382,000 | 22.63% |
| Dyne Therapeutics, Inc. |
No change
8,934,902
|
$61,383,000 | 10.26% |
| Replimune Group Inc |
No change
3,209,627
|
$56,104,000 | 9.38% |
| Generation Bio Co. |
No change
8,278,876
|
$54,309,000 | 9.08% |
| Aerovate Therapeutics, Inc. |
15.00%
2,638,297
|
$41,237,000 | 6.89% |
| Ikena Oncology, Inc. |
No change
5,018,178
|
$22,231,000 | 3.72% |
| Akero Therapeutics Inc |
No change
2,232,251
|
$21,095,000 | 3.53% |
| Vigil Neuroscience, Inc. |
No change
5,836,874
|
$15,059,000 | 2.52% |
| Gemini Therapeutics, Inc. |
No change
5,254,365
|
$8,880,000 | 1.48% |
| Xilio Therapeutics, Inc. |
No change
2,759,344
|
$8,057,000 | 1.35% |
| Magenta Therapeutics Inc |
No change
3,476,536
|
$4,172,000 | 0.70% |
| AvroBio Inc |
No change
4,520,863
|
$4,159,000 | 0.70% |
| F-star Therapeutics, Inc. |
No change
599,524
|
$3,753,000 | 0.63% |
| Cogent Biosciences, Inc. |
Closed
186,487
|
$1,397,000 | |
| Viridian Therapeutics, Inc. |
No change
90,072
|
$1,042,000 | 0.17% |
| Spero Therapeutics Inc |
No change
1,031,160
|
$764,000 | 0.13% |
| No transactions found | |||
| Showing first 500 out of 17 holdings | |||